What should consent cover for experimental or unapproved exosome use?

When an exosome or extracellular-vesicle product is proposed outside standard use, as research or by an unapproved route, a generic aesthetic consent form is insufficient. Exact identity, regulatory status, experimental elements, known and unknown risks, evidence limits, alternatives, cost, data use and access to care after harm should be explained.

This translation has no recorded clinical or medical-language review.

Direct answer

Paying for treatment does not make it a clinical trial; trial registration and ethics review need separate verification.
A signed form cannot correct a product's legal status or weak evidence.
A person should be able to decline, take reflection time and retain access to ordinary care.

Product and status disclosure

Provide the trade name, manufacturer, cellular or biological source, content characterization, lot, manufacturing standard, storage and route in writing. Verify Turkish classification and authorization through an official source. If a US IND or FDA approval is claimed, inspect the number and document; a registration number is not marketing authorization or proof of a positive result.

How to communicate uncertainty

Summarize the number, design, sample, comparator and follow-up of human studies in plain language. If exact-product data are absent, a paper on a similar class should not be presented as direct evidence. Explain infection, immune reaction, unexpected tissue response, delay of established care and long-term unknowns, including when frequency cannot be estimated.

Independent choice and a plan after harm

Compare established alternatives, the co-procedure alone, no treatment and a second opinion. State in advance who provides follow-up, where urgent care is available, how the product record will be shared, where adverse events are reported and how additional-care costs are handled. Consent is an ongoing process and should be updated when new information emerges.

Scope of this article

This content is not diagnosis, prescribing, personal risk assessment or a treatment plan. Sources may be limited to a particular product, device, task, indication or study group.

Sources and evidence limits

These links are editorial starting points used to examine the article's boundaries.

Microneedling for Facial Rejuvenation: A Systematic Review
Foppiani JA et al. · 2025
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Evaluating the Effectiveness and Safety of Radiofrequency for Face and Neck Rejuvenation: A Systematic Review
Austin GK, Struble SL, Quatela VC · 2022
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Energy-Based Devices for the Treatment of Facial Skin Conditions in Skin of Color
Sanyal RD, Fabi SG · 2024
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling – FDA Safety Communication
U.S. Food and Drug Administration (FDA) · 2025
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
A Systematic Review and Meta-Analysis of Efficacy, Safety, and Satisfaction Rates of Laser Combination Treatments vs Laser Monotherapy in Skin Rejuvenation Resurfacing
Pour Mohammad A et al. · 2023
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Outcomes and Adverse Effects of Ablative vs Nonablative Lasers for Skin Resurfacing: A Systematic Review of 1093 Patients
Mirza HN, Mirza FN, Khatri KA · 2021
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Medical Lasers
U.S. Food and Drug Administration (FDA) · 2023
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Public Safety Notification on Exosome Products
U.S. Food and Drug Administration (FDA) · 2019
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Reporting Adverse Events Related to Stem Cells, Exosomes, or Other Regenerative Medicine Products
U.S. Food and Drug Administration (FDA) · 2026
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Minimal Information for Studies of Extracellular Vesicles (MISEV2023)
International Society for Extracellular Vesicles consensus authors · 2024
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review